PMID- 31748961
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1699-3055 (Electronic)
IS  - 1699-048X (Print)
IS  - 1699-048X (Linking)
VI  - 22
IP  - 7
DP  - 2020 Jul
TI  - The efficacy and safety of immune checkpoint inhibitors in non-small cell lung 
      cancer patients of different age groups: a meta-analysis.
PG  - 1146-1154
LID - 10.1007/s12094-019-02241-5 [doi]
AB  - BACKGROUND: Age is closely related to the efficacy of treatment for non-small 
      cell lung cancer (NSCLC) patients. Latest clinical trials have proved the better 
      overall survival (OS) for the use of immune checkpoint inhibitors verse 
      chemotherapy in NSCLC patients. However, we had no clear idea of the efficacy of 
      them in elderly patients. So we conducted a meta-analysis to compare the efficacy 
      of immune checkpoint inhibitors for NSCLC patients of different age groups and 
      summarized overall treatment-related adverse events. MATERIALS AND METHODS: 
      PubMed, EMBASE, Web of Science and the Cochrane Library were searched for all 
      clinical trials in NSCLC until 30th of April 2019. Eligible studies included 
      randomized controlled trials (RCTs) comparing immune checkpoint inhibitors with 
      chemotherapy in NSCLC patients. The hazard ratio (HRs) and 95% confidence 
      intervals (CIs) of OS, progression-free survival or adverse events (AEs) were 
      used. RESULTS: A total of 4994 patients from 8 RCTs were included. Immune 
      checkpoint inhibitors significantly prolonged the OS (HR, 0.73; 95% CI, 
      0.61-0.89) versus chemotherapy in NSCLC patients who were less than 65 years old. 
      Also, they prolonged the OS (HR, 0.74; 95% CI, 0.59-0.93) in NSCLC patients who 
      were more than 65 years old. However, there was no statistical significance of OS 
      (HR, 0.87; 95% CI, 0.57-1.30) among NSCLC patients who were more than 75 years 
      old. It also showed that the single use of immune checkpoint inhibitors had fewer 
      all-grade AEs. CONCLUSION: Regardless of the NSCLC patients who were less or more 
      than 65 years, immune checkpoint inhibitors could achieve better OS than 
      chemotherapy. But there was no significant difference when NSCLC patients who 
      were more than 75 years old. Older patient should be offered immune therapies if 
      it is possible and the mechanism in old age treatment should be further studied.
FAU - Zheng, S-Y
AU  - Zheng SY
AUID- ORCID: 0000-0002-4805-0483
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Cui, H-J
AU  - Cui HJ
AD  - Department of Integrative Oncology, China-Japan Friendship Hospital, 2 Yinghua 
      Dongjie, Hepingli, Beijing, 100029, People's Republic of China. 
      chjzryhyy@sina.com.
FAU - Duan, H
AU  - Duan H
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Peng, Y-M
AU  - Peng YM
AD  - Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, People's 
      Republic of China.
FAU - Li, Q
AU  - Li Q
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Sun, C-Y
AU  - Sun CY
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Zhang, J-Y
AU  - Zhang JY
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Shen, W
AU  - Shen W
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Zhang, X
AU  - Zhang X
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Tan, K
AU  - Tan K
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Jiang, X
AU  - Jiang X
AD  - Beijing University of Chinese Medicine, Beijing, China.
LA  - eng
GR  - 81873396/National Natural Science Foundation of China/
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20191120
PL  - Italy
TA  - Clin Transl Oncol
JT  - Clinical & translational oncology : official publication of the Federation of 
      Spanish Oncology Societies and of the National Cancer Institute of Mexico
JID - 101247119
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Humans
MH  - Immune Checkpoint Inhibitors/*therapeutic use
MH  - Lung Neoplasms/*drug therapy
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Survival Rate
PMC - PMC7260274
OTO - NOTNLM
OT  - Elderly patients
OT  - Immune checkpoint inhibitors
OT  - Meta-analysis
OT  - Non-small cell lung cancer (NSCLC)
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, or publication of this article.
EDAT- 2019/11/22 06:00
MHDA- 2021/03/26 06:00
PMCR- 2019/11/20
CRDT- 2019/11/22 06:00
PHST- 2019/08/30 00:00 [received]
PHST- 2019/10/31 00:00 [accepted]
PHST- 2019/11/22 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2019/11/22 06:00 [entrez]
PHST- 2019/11/20 00:00 [pmc-release]
AID - 10.1007/s12094-019-02241-5 [pii]
AID - 2241 [pii]
AID - 10.1007/s12094-019-02241-5 [doi]
PST - ppublish
SO  - Clin Transl Oncol. 2020 Jul;22(7):1146-1154. doi: 10.1007/s12094-019-02241-5. 
      Epub 2019 Nov 20.